The Biomaterials and Nanobiotechnology Platform is leaded by Professor Jin Chang. The team of the platform consists of 11 professors, 8 associated professors and 7 lecturers.
The research field of the platform is focus on synthesis technology for nanobiomaterials, targeted and controlled release treatment technology, detective technology in vitro, diagnostic technology in vivo and theranostic technology.
The courses that the platform can provide are Biomedical Materials, Micro-Nano biotechnology, Nanomedicine and Formulations, Nanoparticle-based Biosensing, Polymer Materials for Drug Delivery, Transdermal Drug Delivery System, Introduction to Pharmaceutical Science, Pharmaceutics and Advanced Cell Biology.
Prof. Dr. Hussain Ali has been immersed in the realm of Pharmaceutical Nanotechnology since 2009. His doctoral and master's thesis centered around the preparation and meticulous characterization of nanoparticulate drug delivery systems tailored for therapeutic applications. With an extensive background in nanotechnology, he brings a wealth of experience to this dynamic field.
Prof. Ali's research endeavors have gravitated toward the intricate domain of drug delivery systems. His focal points include devising innovative treatments for inflammation and cancer, employing both oral and transdermal routes. Upon joining Quaid-i-Azam University, he broadened his horizons by embarking on research addressing Rheumatoid Arthritis (RA) alongside inflammatory bowel disease (IBD). This strategic expansion stems from the escalating prevalence of RA within the Pakistani populace. Moreover, his research interests further encompass targeted drug delivery to the brain for tackling neurological disorders. In addition to hands-on experimentation, Dr. Ali has embarked on a computational research approach to fine-tune nano-formulation optimization.
The research of Prof. Chen's group is focused on synthesis of biomaterials and development of modern separation and analysis technology. In particular, efforts include a) Development of mixed-mode chromatography stationary phases according to the structure of analytes. b) Design novel chiral stationary phases to establish “single-column detection technology” to improve the quality control efficiency of chiral drugs, and investigate the chiral separation mechanism by molecular simulation and chiral nuclear magnetic resonance. c) Exploitation of magnetic separation technology in the purification of biological samples. Additionally, efforts are extended towards control the morphology and pore structure of silica microspheres, and to optimize HPLC and LC-MS separation and identification methods for complex samples.
(1) Research on the catalytic activity of nanomaterials including metal nanoparticles, metal nanoclusters, graphene oxide, carbon dots, quantum dots, molybdenum disulfide, etc on chemiluminescent reations.
(2) Develop novel chemiluminescent immunoassay, sequence-specific DNA detection method, protease activity assay, and small molecules sensing method based on the unique properties of those nanomaterials.
The research of the Gao group covers medicinal chemistry and molecular targeting, synthetic chemistry and organo catalysis, and computer-aided drug design, aimed at the discovery of functional drug delivery carriers and understanding mechanisms of molecular targeting. Specific areas include a) strategies for development of small molecular anti-cancer drugs for targeted therapy, b) design and development of actively transportable small molecule drugs or protein-drug conjugates, c) discovery and development of novel drug-delivery carriers and pharmaceutics based on supramolecular chemistry, d) computer aided molecular design and modeling for innovative drug discovery and mechanistic study of drug transporters.
The research of the Huang group encompasses the following main areas:
1) Molecular design (AIDD & Chiral Catalyst/ligand Design)
2) XDC Drug Development and Preparation (Protac/RDC...)
3) New Chemical Space Exploration
Nan Li is working in the field of nanomedicine to develop various functional nanomaterials and nanotechnologies for cancer diagnosis and therapy, particular for phototherapy and photodynamic therapy of cancer.
(1) Cancer Immunoengineering
(2) Non-viral Delivery of Nucleic Acid Drugs
(3) Live Cell Mediated Drug Delivery
The research in the group of Wang encompasses four main areas, including 1) Functional polymeric materials (biodegradable polymeric materials, smart polymeric materials such as thermo-sensitive and pH sensitive polymers, dendrimers etc.), 2) Nanotechnology for solubility improvement of water-insoluble drugs, 3) Targeted and controlled drug release systems, and 4) Self-assembled nanostructures for controlled drug release.
The research in the group of Zhao encompasses four main areas, including (1) Stimuli-responsive drug delivery systems; (2) Ferroptosis-targeting nanomedicines; (3) Photo-triggered microtubule inhibitors; (4) Pharmaceutical micelles, biomaterials and nanomaterials.
(1) Development of novel phototherapy molecules for disease treatment
(2) Develop new biological probes to assist disease diagnosis and biological mechanism research
The Biomaterials and Nanobiotechnology Platform is leaded by Professor Jin Chang. The team of the platform consists of 11 professors, 8 associated professors and 7 lecturers.
The research field of the platform is focus on synthesis technology for nanobiomaterials, targeted and controlled release treatment technology, detective technology in vitro, diagnostic technology in vivo and theranostic technology.
The courses that the platform can provide are Biomedical Materials, Micro-Nano biotechnology, Nanomedicine and Formulations, Nanoparticle-based Biosensing, Polymer Materials for Drug Delivery, Transdermal Drug Delivery System, Introduction to Pharmaceutical Science, Pharmaceutics and Advanced Cell Biology.
Prof. Dr. Hussain Ali has been immersed in the realm of Pharmaceutical Nanotechnology since 2009. His doctoral and master's thesis centered around the preparation and meticulous characterization of nanoparticulate drug delivery systems tailored for therapeutic applications. With an extensive background in nanotechnology, he brings a wealth of experience to this dynamic field.
Prof. Ali's research endeavors have gravitated toward the intricate domain of drug delivery systems. His focal points include devising innovative treatments for inflammation and cancer, employing both oral and transdermal routes. Upon joining Quaid-i-Azam University, he broadened his horizons by embarking on research addressing Rheumatoid Arthritis (RA) alongside inflammatory bowel disease (IBD). This strategic expansion stems from the escalating prevalence of RA within the Pakistani populace. Moreover, his research interests further encompass targeted drug delivery to the brain for tackling neurological disorders. In addition to hands-on experimentation, Dr. Ali has embarked on a computational research approach to fine-tune nano-formulation optimization.
The research of Prof. Chen's group is focused on synthesis of biomaterials and development of modern separation and analysis technology. In particular, efforts include a) Development of mixed-mode chromatography stationary phases according to the structure of analytes. b) Design novel chiral stationary phases to establish “single-column detection technology” to improve the quality control efficiency of chiral drugs, and investigate the chiral separation mechanism by molecular simulation and chiral nuclear magnetic resonance. c) Exploitation of magnetic separation technology in the purification of biological samples. Additionally, efforts are extended towards control the morphology and pore structure of silica microspheres, and to optimize HPLC and LC-MS separation and identification methods for complex samples.
(1) Research on the catalytic activity of nanomaterials including metal nanoparticles, metal nanoclusters, graphene oxide, carbon dots, quantum dots, molybdenum disulfide, etc on chemiluminescent reations.
(2) Develop novel chemiluminescent immunoassay, sequence-specific DNA detection method, protease activity assay, and small molecules sensing method based on the unique properties of those nanomaterials.
The research of the Gao group covers medicinal chemistry and molecular targeting, synthetic chemistry and organo catalysis, and computer-aided drug design, aimed at the discovery of functional drug delivery carriers and understanding mechanisms of molecular targeting. Specific areas include a) strategies for development of small molecular anti-cancer drugs for targeted therapy, b) design and development of actively transportable small molecule drugs or protein-drug conjugates, c) discovery and development of novel drug-delivery carriers and pharmaceutics based on supramolecular chemistry, d) computer aided molecular design and modeling for innovative drug discovery and mechanistic study of drug transporters.
The research of the Huang group encompasses the following main areas:
1) Molecular design (AIDD & Chiral Catalyst/ligand Design)
2) XDC Drug Development and Preparation (Protac/RDC...)
3) New Chemical Space Exploration
Nan Li is working in the field of nanomedicine to develop various functional nanomaterials and nanotechnologies for cancer diagnosis and therapy, particular for phototherapy and photodynamic therapy of cancer.
(1) Cancer Immunoengineering
(2) Non-viral Delivery of Nucleic Acid Drugs
(3) Live Cell Mediated Drug Delivery
The research in the group of Wang encompasses four main areas, including 1) Functional polymeric materials (biodegradable polymeric materials, smart polymeric materials such as thermo-sensitive and pH sensitive polymers, dendrimers etc.), 2) Nanotechnology for solubility improvement of water-insoluble drugs, 3) Targeted and controlled drug release systems, and 4) Self-assembled nanostructures for controlled drug release.
The research in the group of Zhao encompasses four main areas, including (1) Stimuli-responsive drug delivery systems; (2) Ferroptosis-targeting nanomedicines; (3) Photo-triggered microtubule inhibitors; (4) Pharmaceutical micelles, biomaterials and nanomaterials.
(1) Development of novel phototherapy molecules for disease treatment
(2) Develop new biological probes to assist disease diagnosis and biological mechanism research
